Latest Europe News

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

Advanced Engineered Materials (ASX:AEM) reported an 85% jump in high purity alumina sales in 1H 2026, with a customer pipeline now valued at US$190 million amid tightening global supply and rising semiconductor industry demand.

RooLife Group (ASX:RLG) has completed a strategic acquisition to bolster its renewable energy division, acquiring project origination and delivery assets in the battery storage and hybrid power market. The deal is scrip-based, with most consideration contingent on future contract milestones.

Rubicon Water's FY26 results reveal an 11.6% revenue drop to $61.1 million and a net loss widening to $15.7 million, impacted by US federal funding delays and currency headwinds. Despite this, the company secured $28.4 million in second-half contracts and holds a $47 million major project pipeline, underpinning confidence for FY27 growth.

Comms Group Limited reported record FY26 revenue and EBITDA growth, driven by organic expansion and TasmaNet acquisition, while progressing the $30m sale of its ICT business to streamline operations and support shareholder returns.

Latitude 66 has finalised the sale of its non-core Piastri Project to Capricorn Metals, converting the deal into approximately A$1.79 million in shares. Alongside a recent royalty portfolio sale, this boosts Latitude 66’s war chest with over A$5 million to fund core exploration in Finland and Western Australia.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

International Graphite Limited has closed a $4.4 million placement, securing cornerstone investors including Xcelsior Capital to fund expansion of graphite processing operations in Australia and Europe.

James Hardie Industries has agreed to divest its European Fermacell sustainable walling and flooring business to Holcim for €840 million, while planning to close its European fiber cement operations and launch a $250 million share buyback.

IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.